NASDAQ:RIGL Rigel Pharmaceuticals (RIGL) Stock Price, News & Analysis $10.75 -0.15 (-1.38%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$10.65▼$11.2450-Day Range$7.73▼$11.2552-Week Range$7.12▼$17.30Volume59,571 shsAverage Volume156,058 shsMarket Capitalization$188.77 millionP/E RatioN/ADividend YieldN/APrice Target$58.13 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Rigel Pharmaceuticals alerts: Email Address Rigel Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside440.7% Upside$58.13 Price TargetShort InterestHealthy3.56% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.27Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.33) to $0.20 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.99 out of 5 starsMedical Sector372nd out of 936 stocksPharmaceutical Preparations Industry174th out of 436 stocks 3.3 Analyst's Opinion Consensus RatingRigel Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageRigel Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Rigel Pharmaceuticals' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.56% of the float of Rigel Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRigel Pharmaceuticals has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Rigel Pharmaceuticals has recently decreased by 5.45%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldRigel Pharmaceuticals does not currently pay a dividend.Dividend GrowthRigel Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RIGL. Previous Next 2.9 News and Social Media Coverage News SentimentRigel Pharmaceuticals has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Rigel Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for RIGL on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows6 people have added Rigel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rigel Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.04% of the stock of Rigel Pharmaceuticals is held by insiders.Percentage Held by Institutions66.23% of the stock of Rigel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Rigel Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rigel Pharmaceuticals are expected to grow in the coming year, from ($1.33) to $0.20 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rigel Pharmaceuticals is -8.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rigel Pharmaceuticals is -8.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Rigel Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Rigel Pharmaceuticals Stock (NASDAQ:RIGL)Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.Read More RIGL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RIGL Stock News HeadlinesJuly 24 at 7:17 AM | seekingalpha.comRigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow PotentialJuly 19, 2024 | finance.yahoo.comRigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Intrinsic Value Is Potentially 87% Above Its Share PriceJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 12, 2024 | prnewswire.comRigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)June 25, 2024 | prnewswire.comRigel Announces Reverse Stock SplitJune 24, 2024 | prnewswire.comRigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug ApplicationJune 17, 2024 | investorplace.comPenny Stock Picks: 3 Companies Poised to Graduate to the Big LeaguesJune 14, 2024 | prnewswire.comRigel Announces Five Presentations at the EHA2024 Hybrid CongressJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.June 3, 2024 | prnewswire.comRigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual MeetingMay 30, 2024 | prnewswire.comRigel to Present at the Jefferies Global Healthcare ConferenceMay 23, 2024 | prnewswire.comRigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid CongressMay 10, 2024 | finance.yahoo.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Analysts Are Pretty Bullish On The Stock After Recent ResultsMay 8, 2024 | finanznachrichten.deRigel Pharmaceuticals, Inc.: Rigel Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed on Rigel’s Consistent Performance and Growth ProspectsMay 8, 2024 | finance.yahoo.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comRigel Pharmaceuticals Inc (RIGL) Q1 2024 Earnings Call Transcript Highlights: Strategic Moves ...May 7, 2024 | investorplace.comRIGL Stock Earnings: Rigel Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024See More Headlines Receive RIGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rigel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Estimated)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:RIGL CUSIP76655960 CIK1034842 Webwww.rigel.com Phone(650) 624-1100Fax650-624-1101Employees160Year Founded1996Price Target and Rating Average Stock Price Target$58.13 High Stock Price Target$150.00 Low Stock Price Target$12.50 Potential Upside/Downside+440.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-25,090,000.00 Net Margins-16.45% Pretax Margin-16.45% Return on EquityN/A Return on Assets-16.64% Debt Debt-to-Equity RatioN/A Current Ratio1.26 Quick Ratio1.17 Sales & Book Value Annual Sales$116.88 million Price / Sales1.62 Cash FlowN/A Price / Cash FlowN/A Book Value($1.64) per share Price / Book-6.55Miscellaneous Outstanding Shares17,560,000Free Float15,971,000Market Cap$188.77 million OptionableOptionable Beta0.96 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Raul R. Rodriguez (Age 63)President, CEO & Director Comp: $1.17MMr. Dean L. Schorno CPA (Age 61)Executive VP & CFO Comp: $736.72kMr. Raymond J. Furey J.D. (Age 56)Executive VP, General Counsel & Corporate Secretary Comp: $683kMr. David A. Santos (Age 61)Executive VP & Chief Commercial Officer Comp: $737.18kMs. Julie PatelSenior VP of Human ResourcesDr. Esteban S. Masuda (Age 62)Executive Vice President of Research Comp: $537.21kMr. Joseph Lasaga (Age 49)Executive VP & Chief Business Officer Dr. Lisa Rojkjaer M.D. (Age 58)Executive VP & Chief Medical Officer Mr. Tarek SallamVice President of MarketingMore ExecutivesKey CompetitorsG1 TherapeuticsNASDAQ:GTHXUrovant SciencesNASDAQ:UROVEmergent BioSolutionsNYSE:EBSLexicon PharmaceuticalsNASDAQ:LXRXVanda PharmaceuticalsNASDAQ:VNDAView All CompetitorsInstitutional OwnershipBank of New York Mellon CorpSold 464,517 shares on 7/26/2024Ownership: 0.339%SG Americas Securities LLCSold 6,290 shares on 7/12/2024Ownership: 0.091%Jacobs Levy Equity Management Inc.Sold 394,636 shares on 5/16/2024Ownership: 1.305%Bayesian Capital Management LPBought 19,100 shares on 5/16/2024Ownership: 0.017%California State Teachers Retirement SystemSold 10,960 shares on 5/16/2024Ownership: 0.010%View All Institutional Transactions RIGL Stock Analysis - Frequently Asked Questions How have RIGL shares performed this year? Rigel Pharmaceuticals' stock was trading at $14.50 at the beginning of 2024. Since then, RIGL stock has decreased by 25.9% and is now trading at $10.75. View the best growth stocks for 2024 here. How were Rigel Pharmaceuticals' earnings last quarter? Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) issued its quarterly earnings results on Tuesday, May, 7th. The biotechnology company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by $0.20. The biotechnology company had revenue of $29.53 million for the quarter, compared to analysts' expectations of $31.28 million. When did Rigel Pharmaceuticals' stock split? Rigel Pharmaceuticals shares reverse split on the morning of Thursday, June 27th 2024. The 1-10 reverse split was announced on Thursday, June 27th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 27th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Raul Rodriguez's approval rating as Rigel Pharmaceuticals' CEO? 6 employees have rated Rigel Pharmaceuticals Chief Executive Officer Raul Rodriguez on Glassdoor.com. Raul Rodriguez has an approval rating of 84% among the company's employees. Who are Rigel Pharmaceuticals' major shareholders? Rigel Pharmaceuticals' top institutional shareholders include Bank of New York Mellon Corp (0.34%) and SG Americas Securities LLC (0.09%). Insiders that own company stock include Raul R Rodriguez, Dean L Schorno and David A Santos. View institutional ownership trends. How do I buy shares of Rigel Pharmaceuticals? Shares of RIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Rigel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rigel Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Aeterna Zentaris (AEZS), KushCo (KSHB) and Novan (NOVN). This page (NASDAQ:RIGL) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rigel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rigel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
